SynthesisAJNR. American journal of neuroradiology2025
Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma: A Meta-Analysis of Large Randomized Controlled Trials.
Synthesis in AJNR. American journal of neuroradiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Middle meningeal artery embolization for chronic subdural hematoma: meta-analysis of three randomized controlled trials and review of ongoing trials.Acta neurochirurgica · 2025Pooled it
- Middle Meningeal Artery Embolization as Standalone Therapy for Chronic Subdural Hematoma with Radiological Herniation Features: A Case Report.Neurology international · 2026Article
- Chronic Subdural Hematoma: A Review of Current Knowledge, Treatment Modalities, and Clinical Trials of Middle Meningeal Artery Embolization.Neurology. Clinical practice · 2025Review
- The subdural membrane: unraveling the pathophysiology and treatment of chronic subdural hematoma.Frontiers in surgery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMiddle meningeal artery embolization (MMAE) has emerged as a novel treatment for non-acute subdural hematoma (SDH), particularly for reducing the risk of SDH recurrence. Recently, 5 randomized controlled trials (RCTs) of MMAE as an adjunct to conventional management (surgical or observant) have concluded their investigation and reported their outcomes. PURPOSE: Our goal was to synthesize trial results to provide more definitive guidance on the role of MMAE in the management of non-acute SDH. DATA SOURCES: The MEDLINE database from inception up to November 23, 2024 was used. English-language clinical articles reporting large randomized controlled trials ( STUDY SELECTION: Five trials were identified-EMBOLISE, STEM, MAGIC-MT, EMPROTECT, and MEMBRANE. DATA ANALYSIS: The primary efficacy end point was SDH treatment failure (broadly defined as SDH recurrence or requirement of surgical rescue) within 3 to 6 months. Safety end points include death and stroke. DATA SYNTHESIS: There was significant heterogeneity in terms of patient populations as well as reported outcomes. Overall, MMAE was associated with significantly lower odds of SDH treatment failure (OR 0.51 [95% CI 0.39-0.67], LIMITATIONS: Our meta-analysis is limited by selection bias and high heterogeneity in study design and reported outcomes.
conclusionsThis study provides high-level evidence that, for patients with non-acute SDH, MMAE is a safe and effective adjunct to conventional management for preventing treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.